We are live on ! Find out more
JJ

Johnson & Johnson Portfolio holdings

AUM $799M Turnover 17.65%
1-Year Est. Return 253.51%
This Fund
S&P 500
This Quarter Est. Return
+1.66%
1 Year Est. Return
+253.51%
3 Year Est. Return
+280.64%
5 Year Est. Return
+320.83%
10 Year Est. Return
–
AUM
$342M
AUM Growth
-$44.3M
Cap. Flow
$0
Cap. Flow %
0%
Top 10 Hldgs %
97.19%
Holding
20
New
–
Increased
–
Reduced
–
Closed
–
Avg Time Held
2.6 years
Top 10 Avg Time Held
1.9 years
Top 20 Avg Time Held
2.4 years

Top Buys

No buys this quarter

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
PTGX icon
1
Protagonist Therapeutics
PTGX
$8.82B
$118M 34.65%
2,449,183
– –
2021 Q3
14 quarters
CVRX icon
2
CVRx
CVRX
$35.7M
$50.2M 14.68%
4,103,430
– –
2021 Q3
14 quarters
MGTX icon
3
MeiraGTx Holdings
MGTX
$904M
$45M 13.17%
6,641,064
– –
2021 Q3
14 quarters
LEGN icon
4
Legend Biotech
LEGN
$3.7B
$27.6M 8.08%
814,586
– –
2021 Q3
14 quarters
RAPP icon
5
Rapport Therapeutics
RAPP
$1.36B
$25.1M 7.33%
2,498,051
– –
2024 Q2
3 quarters
PRCT icon
6
Procept Biorobotics
PRCT
$1B
$20.9M 6.1%
357,939
– –
2021 Q3
14 quarters
NBTX icon
7
Nanobiotix
NBTX
$1.08B
$20.1M 5.89%
5,623,816
– –
2023 Q3
6 quarters
CTNM icon
8
Contineum Therapeutics
CTNM
$306M
$13.8M 4.04%
1,979,173
– –
2024 Q2
3 quarters
XNCR icon
9
Xencor
XNCR
$1.74B
$7.96M 2.33%
748,062
– –
2021 Q4
13 quarters
ARWR icon
10
Arrowhead Research
ARWR
$8.25B
$3.15M 0.92%
247,598
– –
2021 Q3
14 quarters
FATE icon
11
Fate Therapeutics
FATE
$232M
$2.67M 0.78%
3,379,064
– –
2021 Q3
14 quarters
RLYB icon
12
Rallybio
RLYB
$89.8M
$2.38M 0.7%
454,545
– –
2024 Q2
3 quarters
NMRA icon
13
Neumora Therapeutics
NMRA
$66.6M
$1.85M 0.54%
1,849,445
– –
2023 Q3
6 quarters
NNOX icon
14
Nano X Imaging
NNOX
$40.1M
$793K 0.23%
158,852
– –
2021 Q4
13 quarters
VOR icon
15
Vor Biopharma
VOR
$1.11B
$771K 0.23%
53,733
– –
2021 Q3
14 quarters
LYEL icon
16
Lyell Immunopharma
LYEL
$196M
$443K 0.13%
41,166
– –
2024 Q4
1 quarter
LAB icon
17
Standard BioTools
LAB
$248M
$337K 0.1%
311,967
– –
2024 Q1
4 quarters
ACET icon
18
Adicet Bio
ACET
$45.8M
$275K 0.08%
22,780
– –
2021 Q3
14 quarters
HLSQ
19
Tessera Defense and Homeland Security Inc.
HLSQ
$2.15M
$53.8K 0.02%
510
– –
2021 Q3
14 quarters
SENS icon
20
Senseonics Holdings Inc
SENS
$428M
$35.8K 0.01%
2,731
– –
2021 Q3
14 quarters

Similar funds

SEM
Suncoast Equity Management Tampa, Florida $798M AUM 14.62% 1-Year Est. Return
TI
TrueMark Investments Chicago, Illinois $798M AUM 25.52% 1-Year Est. Return
GIM
Garden Investment Management Greenwich, Connecticut $798M AUM 18.61% 1-Year Est. Return
QCMNJ
Quantum Capital Management (New Jersey) Northfield, New Jersey $798M AUM 8.86% 1-Year Est. Return
LOPW
Live Oak Private Wealth Wilmington, North Carolina $800M AUM 24.59% 1-Year Est. Return
HW
HORAN Wealth Cincinnati, Ohio $800M AUM 23.65% 1-Year Est. Return
CCM
Corsair Capital Management New York $800M AUM 94.38% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 22.73% 1-Year Est. Return

Johnson & Johnson's Q1 2025 Portfolio in Review

As of Q1 2025, Johnson & Johnson held 20 positions worth $342M, down 11% from $386M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Trading was light in Q1 2025: portfolio turnover was 0%. Johnson & Johnson opened no new positions and made no exits, leaving the 20-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Johnson & Johnson's ten largest holdings make up 97% of its $342M portfolio in Q1 2025.
  • Johnson & Johnson opened 0 new positions and closed 0 in Q1 2025.
  • Johnson & Johnson's portfolio value fell 11% quarter-over-quarter to $342M.

Based on Johnson & Johnson's 13F filing for Q1 2025, filed 7 May 2025.